Ramucirumab is primarily used in the treatment of certain types of cancer. It is a monoclonal antibody that targets the vascular endothelial growth factor receptor-2 (VEGFR-2), which plays a key role in the formation of new blood vessels that supply tumors. By inhibiting VEGFR-2, ramucirumab helps to cut off the blood supply to cancer cells, thereby slowing tumor growth and spread. It is commonly prescribed for advanced or metastatic gastric cancer, particularly when the cancer has progressed after initial chemotherapy. Additionally, it is used in combination with other chemotherapy drugs to treat non-small cell lung cancer (NSCLC) and colorectal cancer in specific cases. Ramucirumab is administered intravenously and is often part of a broader treatment plan tailored to the patient's condition and response to therapy.